Risperdal is a powerful antipsychotic drug manufactured by Johnson and Johnson Co., was approved by the FDA in 1993 for the treatment of condition like schizophrenia in adults.  Later in 2007 this drug was approved to treat schizophrenia and bipolar disorder in adults and youth between the ages of 13 and 17.  

According to U.S. Department of Justice, the drug was also promoted for off label uses, including the treatment of attention deficit hyperactivity disorder (ADHD).

In the year 2005, a black box warning was issued for Risperdal drug due to an increased risk of death in patients with dementia over the age of 60.  In 2006, Duke University conducted a study of the drug in which they found users of Risperdal drug had a higher chance of male breast growth called gynecomastia than users of any other anti-psychotic. To get more details about Risperdal Gynecomastia Lawsuit, one can simply head to http://www.risperdalgynecomastialawsuitcenter.com/risperdal-male-breasts-lawsuit.asp.

Despite this info, the FDA approved the drug for use in treatment of manic disorders in teenagers in 2007, and Johnson and Johnson continued to market it the drug to youth.

In 2010 the first case was filed against Risperdal manufacturers by a man who was marketed Risperdal drug as a teen for unapproved uses and suffered from depression and embarrassment due to unnatural breast growth.  Also, the man was required to pursue costly and potentially painful surgery in order to treat this condition.